KZR - BULLISHPurchased this stock at .85 cents on the 15th, based on an article on oct 10th, today news came out states:
Regulatory Approval: The approval from China's National Medical Products Administration (NMPA) for the Phase 2b PALIZADE trial signifies regulatory confidence in the potential of zetomipzomib.